Introduction {#S1}
============

The existence of a conserved Open Reading Frame (ORF) located on the antisense strand of the proviral genome of the Human Immunodeficiency Virus type 1 (HIV-1) was first suggested in 1988 ([@B21]). In this pioneer study, the antisense ORF was proposed to encode for a highly hydrophobic protein of 189 amino acids, later named AntiSense Protein (ASP). The very first detection of ASP in HIV-1-infected cells was achieved by the group of C. Vaquero in 2002 ([@B5]). The same year, our group demonstrated the existence of Human-T-leukemia Virus Type 1 (HTLV-1) B-ZIP Factor (HBZ), another antisense retroviral protein ([@B12]). Following this discovery, we and others have investigated the antisense transcriptional activity of HIV-1 ([@B20]; [@B17]; [@B18]; [@B2]) and studied ASP both *in vitro* and *ex vivo*. In collaboration with others, we thus successively reported (i) the detection of ASP at the plasma membrane of transfected cells ([@B9]), (ii) the involvement of ASP in the autophagic flux of ASP-expressing cells ([@B29]) and importantly, (iii) the detection of a cytotoxic T CD8+ response directed against several domains of ASP in HIV-1 infected patients ([@B4]). In addition, our group recently showed the concomitant emergence of the 10th gene of HIV-1, the *asp* gene, with the pandemic group M of HIV-1, as well as the existence of a selection pressure acting to maintain *asp* within this group ([@B8]). Altogether, these findings brought us to argue that ASP might be involved in the spreading or in the virulence of HIV-1. However, the role endorsed by ASP in the pathophysiology of HIV-1 infection and its underlying cellular mechanisms remain to be unraveled. One way to demonstrate the *in vivo* expression and immunogenicity of ASP, and to assess when ASP is expressed during the course of HIV-1 infection consists in detecting the humoral response elicited against ASP in infected patients. The study from the group of C. Vaquero conducted in 1995 previously revealed by western blot an *in vitro* translated ASP after immuno-precipitation by several serum samples from HIV-1-infected individuals, suggesting the existence of antibodies targeting ASP *in vivo* ([@B30]). However, these promising results have never been reproduced nor confirmed by any other study. In the present study, we developed a specific and quantitative luminescent assay to detect antibodies targeting ASP in a panel of plasma samples from HIV-1-infected patients under antiretroviral therapy (ART), ART-naive or who discontinued antiretroviral drugs (ARV). The LIPS assay presents several advantages. First, the recombinant proteins used in LIPS are obtained from a soluble crude cell lysate extracted from transfected cells, which prevents complex purification protocols. Second, the method used to obtain the recombinant antigens allows the use of native, non-reducing conditions for the antigens. Third, LIPS is a fluid phase immunoassay using antigens in their native conformation and is well suited to detect antibodies directed against linear and conformational epitopes ([@B7]). In the patients tested positive for ASP-specific antibodies, we further delineated the domains of ASP targeted by the antibodies by using ASP deletion mutants. In conclusion, in this study, we provided evidence of the existence of antibodies directed against ASP *in vivo*, we gave insights into the targeted epitopes of ASP, and, for the first time, we described the humoral response against ASP in the plasma of HIV-1-infected individuals.

Materials and Methods {#S2}
=====================

Human Plasma Samples {#S2.SS1}
--------------------

### ANRS 12174 Trial {#S2.SS1.SSS1}

Subjects were HIV-1-infected breastfeeding women from Burkina Faso whose infants were enrolled in the PROMISE-PEP trial. All mothers received AZT during pregnancy and labor but they were not eligible for ART post-partum according to national recommendations at the period the trial was conducted (above 350 CD4 cell/μL of blood) ([@B22]). Written informed consents were obtained from the mother or the legal representative prior to enrollment (NCT00640263). Plasma samples were screened at week 38 post-partum and at intermediate time points when necessary. The study was conducted according to the sponsor (Agence Nationale de Recherche sur le Sida et les hépatites virales; ANRS) ethic charter, Good Clinical Practices and the principles of the Helsinki declaration. The protocol was approved by the National Ethic Committee (n° 2008-0039).

### ANRS CO2 SEROCO Cohort {#S2.SS1.SSS2}

Subjects, enrolled from 1988 to 1995 (i) were infected no more than 12 months prior to enrollment and (ii) were free of AIDS related diseases at inclusion ([@B13]). No ART were received before inclusion and during the study until 1996. A follow-up was performed every 6 months until 2009. A written informed consent was obtained from patients, in line with the guidelines formulated by local ethical committees.

### ANRS HIV Controller CO21 CODEX Cohort {#S2.SS1.SSS3}

Enrolled subjects met the following criteria: (i) naive for ART, (ii) seropositive for at least 5 years before enrollment, and (iii) with a viral load below 400 HIV-1 RNA copies/mL in the five consecutive measurements before inclusion ([@B16]; [@B27]) Follow-up was performed at least once a year for 6 years. All patients gave a written informed consent. The C021 CODEX cohort was approved by the Ethics Review Committee of Ile de France VII and performed in compliance with the tenets of the Declaration of Helsinki.

### Patients Under ART {#S2.SS1.SSS4}

We used plasma isolated from total blood samples collected from 20 patients under ART during their follow-up at the University Hospital of Montpellier. Subjects enrolled in the cohort provided written informed consent. The study was then approved by Institutional Ethics Committee (RCB n° 2011-A01566-35, AC-2011-1405).

### Uninfected Donors {#S2.SS1.SSS5}

Plasma samples were collected from French seronegative blood donors (Etablissement Français du Sang) and from breastfeeding, seronegative women from Zambia. The study was approved by the Excellency in Research Ethics and Science Converge Institutional Review Board (00005948 IRB number) in Lusaka, Zambia.

Antigens Preparation {#S2.SS2}
--------------------

Flag-nanoluciferase cDNA (kindly gifted by Dr. Olivier Moncorgé, IRIM) was fused with the codon-optimized cDNA sequence of full-length ASP that has been previously described ([@B29]), or with ASP deletion mutants. The sequences of nano-ASP and of the 26--189 and 60--189 mutants were generated by overlapping PCR from the nanoluciferase and ASP cDNA sequences. For nano-ASP, we used the following primers: nanoluciferase forward 5′-ACGTGAATTCGCC GCCATGGACTACAAGGACGACGATGACAAGGTCTTCACA CTCGAAG-3′ and reverse 5′-CACGGAATTCAGCTCGAGC CGCTGGAGCCCGCCAGAATGCGTTC-3′, ASP forward 5′-GAACGCATTCTGGCGGGCTCCAGCGGCTCGAGTCCCCA GACCGTGAG-3′ and reverse 5′-ACTGCGAATTCACTGCA GCTCCACGCAGGAGTTCAGCAGCACCTGATTCAGCAGT GA-3′. For the 26--189 mutant, the following primer sets were used: nanoluciferase forward 5′-ACGTGAATTCGCCGCCA TGGACTACAAGGACGACGATGACAAGGTCTTCACACTCG AAG-3′ and reverse 5′-GTTATCGGGACTCGAGCCGCTGGAG CCCGCCAGAATGCGTTC-3′, ASP forward 5′-TCCAGCGGC TCGAGTCCCGATAACAACTGCCTG-3′ and reverse 5′-ACTGCGAATTCACTGCAGCTCCACGCAGGAGTTCAGCA GCACCTGATTCAGCAGTGA-3′. For the 60--189 mutant, the following primer sets were used: nanoluciferase forward 5′-ACGTGAATTCGCCGCCATGGACTACAAGGACGACGATGA CAAGGTCTTCACACTCGAAG-3′ and reverse 5′- CAGGGC GGTACTCGAGCCGCTGGAGCCCGCCAGAATGCGTTC-3′; ASP forward 5′-TCCAGCGGCTCGAGTACCGCCCTGTTTT CTCTGTGC-3′ and reverse 5′-ACTGCGAATTCACTGCAGC TCCACGCAGGAGTTCAGCAGCACCTGATTCACAGTGA-3′. The 1--62 and 1--141 nano-ASP deletion mutants were generated from the full-length cDNA sequence of nano-ASP with the forward primer 5′-ACGTGAATTCG CCGCCATGGACTACAAGGACGACGATGACAAGGTCTTCA CACTCGAAG-3′ and the reverse primer 5′-ACTGCGAATTCA GGCGGTGGGGATGGGGGCCTTGTTCCT-3′ (1--62 mutant) or 5′-ATGCTTGAATTCTACGATGTA GGCGCCTC-3′ (1--141 mutant). The coding sequences of nano-ASP and nano-Asp mutants were inserted into p-CAGGS, a mammalian expression vector. Vectors encoding for each construction were transfected into HEK 293T cells using polyethyleneimine (Polysciences Inc.) for 48 h before cell harvest and lysis.

Luciferase Immuno-Precipitation System {#S2.SS3}
--------------------------------------

Luciferase Immuno-Precipitation System (LIPS) assay was performed following the protocol described by [@B7] except for the washing steps which were performed by centrifugation. Briefly, plasma samples were incubated with nano-ASP-containing cell lysates. Immune complexes were then precipitated by adding A/G coated sepharose beads (Thermo Scientific) and the luminescence was revealed by adding the substrate of the nanoluciferase (PROMEGA) and quantified on a Berthold luminescence reader. Plasma samples were added at a final dilution of 1/100 in the reaction. For all LIPS reactions, we initially added the amount of nano-ASP-containing cell lysates required to get a luminescence signal of 1.10^7^ light units. The signal obtained from all LIPS reactions (except for the LIPS reactions using ASP mutants) was normalized according to a calibration standard. This standard consisted in luminescent values obtained by performing LIPS reactions using several dilutions of an anti-FLAG antibody (Bethyl) able to precipitate nano-ASP. In experiments using ASP mutants, the signal was normalized by substracting the signal obtained with the nanoluciferase alone for the same plasma sample. Normalized luminescent signal is expressed as Relative Light Units (RLU). The monoclonal antibody against ASP used to test the LIPS was produced by EUROGENTEC from mice immunized with an HXB2-derived peptide.

Statistics {#S2.SS4}
----------

The cut-off for positive anti-ASP antibody response was computed from luminescent values obtained with plasma from the nine Zambian and the 20 French uninfected individuals (Z score = 4, which corresponds to a luminescent value of 48,000 RLU).

Results {#S3}
=======

Development of a Quantitative Assay to Detect Antibodies Against ASP in the Plasma of HIV-1-Infected Patients {#S3.SS1}
-------------------------------------------------------------------------------------------------------------

The LIPS allows for the detection of specific antibodies elicited against pathogens in patients ([@B6], [@B7]). In this assay, a luciferase is fused to the antigen of interest, and plasma samples are incubated with cell lysates containing this fusion protein. After an immuno-precipitation step, the presence of antigen-specific antibodies in the plasma of patients is revealed by the luminescence signal emitted by the luciferase. To detect anti-ASP antibodies in the plasma of HIV-1 infected patients, we used a codon-optimized ASP derived from pNL4-3 fused to the nano-luciferase protein (nano-ASP). We first tested the assay with a monoclonal antibody targeting the residues 47 to 62 of ASP, and we obtained a luminescent signal proportional to the concentration of the anti-ASP monoclonal antibody added to the reaction, while no specific signal was obtained when using the nano-luciferase protein alone ([Supplementary Figure S1](#DS1){ref-type="supplementary-material"}). Therefore, we developed an assay that allows for the specific and quantitative immuno-precipitation of nano-ASP. Using LIPS assay, we then evaluated the presence of specific anti-ASP antibodies in the plasma samples of HIV-1-infected patients.

Antibodies to ASP Are Detected in Untreated HIV-1-Infected Patients {#S3.SS2}
-------------------------------------------------------------------

We assessed the presence of antibodies against ASP in the plasma from two groups of HIV-1 infected individuals: a group of European patients under ART and a group of African patients who discontinued ARV ([@B22]). The group of African patients were pregnant women recruited for the ANRS 12174 clinical trial ([@B22]). In this trial, women received zidovudine as prophylaxis for 4--16 weeks before delivery followed by a combination of zidovudine and lamivudine for 7 days after delivery ([Table 1](#T1){ref-type="table"}). Maternal prophylaxis was stopped at day 7 after patients gave birth, and plasma samples were then regularly collected up to 41 weeks following ARV cessation. The results presented [Figure 1](#F1){ref-type="fig"} were obtained on plasma samples collected from the African patients 37 weeks after ARV cessation (W37).

###### 

Immuno-virological parameters of the patients belonging to the cohort ANRS 12174 (PROMISE-PEP study).

  **Patient**   **Ethnical**   **ARV received**   **Duration of**   **Time after ARV**   **Viremia (copies of HIV-1**   **CD4 T cells/**
  ------------- -------------- ------------------ ----------------- -------------------- ------------------------------ ------------------
  P\#1          African        ZDV                11                37                   1146000                        403
  P\#2          African        ZDV                16                37                   609800                         536
  P\#3          African        ZDV                11                37                   NA                             NA
  P\#4          African        ZDV                14                37                   438900                         522
  P\#5          African        ZDV                10                37                   NA                             NA
  P\#6          African        ZDV                8                 37                   338600                         395
  P\#7          African        ZDV                7                 0                    17280                          NA
                                                                    5                    NA                             NA
                                                                    13                   2492000                        536
                                                                    25                   NA                             NA
                                                                    37                   NA                             NA
                                                                    41                   1437000                        523
  P\#8          African        ZDV                6                 37                   92330                          468
  P\#9          African        ZDV                7                 0                    50320                          NA
                                                                    13                   279400                         367
                                                                    25                   NA                             NA
                                                                    37                   NA                             NA
                                                                    41                   394100                         421
  P\#10         African        ZDV                13                37                   NA                             NA
  P\#11         African        ZDV                5                 25                   NA                             NA
  P\#12         African        ZDV                0                 37                   1712                           728
  P\#13         African        ZDV                13                37                   9069                           4057
  P\#14         African        ZDV                8                 37                   318700                         729
  P\#15         African        ZDV                14                37                   250400                         545
  P\#16         African        ZDV                4                 0                    Undetectable                   NA
                                                                    14                   NA                             NA
                                                                    18                   21160                          477
                                                                    25                   NA                             NA
                                                                    37                   3931                           831
  P\#17         African        ZDV                11                37                   17210                          847
  P\#18         African        ZDV                6                 37                   1128000                        372
  P\#19         African        ZDV                2                 37                   NA                             NA

ARV, Antiretroviral agent; ZDV, zidovudine. NA, not available.

![Antibodies against ASP are detected in HIV-1-infected patients. **(A)** Anti-ASP LIPS was conducted on the plasma of HIV-1 infected-patients from two groups: one group of patients from Europe under ART (HIV+ \[ART\]; *N* = 20) and one group of patients from Africa cleared of any ARV for 37 weeks (HIV+; *N* = 19) (ANRS12174 trial). LIPS was also conducted on the plasma of patients from two seronegative control groups originating from France (*N* = 20) and Zambia (*N* = 9). Signal is expressed as Relative Light Units (RLU). Data shown are the mean of the median of three independent experiments performed in triplicates. **(B)** Plasma samples for Pat \#7, Pat \#9, and Pat \#16, were serially diluted and LIPS was performed on each dilution. Signal is expressed as RLU. Data shown represent the median (plus min and max values) of one representative experiment performed in triplicate. Dotted line represents the cut-off value (48,000 RLU).](fmicb-11-00020-g001){#F1}

We used two groups of uninfected individuals as a control: a group of breastfeeding women from Africa, and a group of European individuals ([Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Using both control groups, the cut-off for positive anti-ASP response was set-up at 48,000 RLU (see section "Materials and Methods"). In the plasma of patients under ART, we observed a signal similar to that obtained in the plasma of the uninfected individuals. However, we observed a positive signal in 3 of the 19 plasma samples collected from the African patients at W37, indicating the presence of antibodies against ASP in the plasma of these three patients (patients \#7, \#9, and \#16, [Figure 1A](#F1){ref-type="fig"}). We then determined the titer of ASP-specific antibodies in the plasma of patients \#7, \#9, and \#16 at W37 by performing serial dilutions of the plasma samples ([Figure 1B](#F1){ref-type="fig"}). Patients \#7 and \#9 displayed ASP-antibody titers of 1/200 and 1/100, respectively. In accordance with its higher luminescence signal, the patient \#16 showed an ASP-antibody titer of 1/800. Altogether, we detected antibodies against ASP in 3 out of the 19 HIV-1-infected patients (15%) who discontinued ARV, but not in patients under ART.

Antibody Response to ASP Is Dynamic Over Months {#S3.SS3}
-----------------------------------------------

To evaluate the evolution of the antibody response to ASP overtime, we searched for ASP-specific antibodies in the plasma samples of Pat \#7, \#9, and \#16 which were collected at different times from ARV cessation to W37, as previously mentioned ([@B22]) ([Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Interestingly, the anti-ASP antibody response fluctuated differently following ARV cessation in the plasma of these three patients. In the plasma of Pat \#16, the response to ASP declined overtime, though it remained the highest antibody response to ASP among the three patients, whatever the time points considered. On the contrary, anti-ASP response remained quite stable in the plasma of Pat \#9 during the follow-up. For Pat \#9 and \#16 plasma, antibodies against ASP were detected at the time of ARV cessation, while they only became detectable 25 weeks after ARV cessation in Pat \#7. Levels of antibodies to ASP then increased up to 37 weeks post-ARV cessation in Pat \#7, concomitantly to a decrease in viral loads. Of note, the plasma of Pat \#16 displayed sustained low viremia and increased levels of CD4+ T cells between ARV cessation and W37 ([Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}), while the level of CD4+ T cells remained stable for Pat \#7 and \#9 during the follow-up. Overall, the antibody response in the plasma of Pat \#7, \#9, and \#16 to ASP fluctuated after ARV cessation in a patient specific manner.

![The Antibody response-targeting ASP fluctuates following ARV cessation. LIPS was conducted on the plasma samples collected from Pat \#7, Pat \#9, and Pat \#16 at different weeks after ARV cessation. Signal is expressed as Relative Light Units (RLU). Data shown represent the median (plus min and max values) of one representative experiment performed in triplicates. Values of viremia (number of HIV-1 RNA copies per mL) measured in the context of the ANRS12174 trial are also represented. For Pat \#16, values of viremia are indicated at each time point. Dotted line represents the cut-off value (48,000 RLU).](fmicb-11-00020-g002){#F2}

Antibodies to ASP Are Not Detected in Patients Under ART {#S3.SS4}
--------------------------------------------------------

Patients under ART did not show any specific signal for anti-ASP antibodies ([Figure 1A](#F1){ref-type="fig"}). To further investigate the fluctuations of the antibody response to ASP upon ART initiation, we performed LIPS assay on the plasma of 10 patients from the French ANRS SEROCO cohort (Multicentric Cohort of HIV Positive Patients), before and after they initiated ART ([@B13]) ([Figure 3A](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Strikingly, we detected a strong signal in the plasma of 1 of the 10 patients prior to ART (Pat \#20 at 2.5 years post-enrollment, i.e., 3 years before ART initiation), but we did not detect any specific signal in the plasma of this same patient 8 years after ART initiation ([Table 2](#T2){ref-type="table"}). To further characterize the response developed against ASP in Pat \#20, we conducted LIPS assay on plasma samples collected at two additional times post-enrollment, respectively 5 years before and 2 years after ART initiation ([Figure 3B](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Interestingly, the loss of antibody response to ASP observed in the plasma of Pat \#20 was already observed 2 years after ART initiation and seemed to be sustained for up to 8 years. Besides, antibodies to ASP were barely detectable in this patient at enrollment (5 years before ART), while increased levels were detected 2.5 years post-enrollment (i.e., 3 years before ART). As patients from the SEROCO cohort were infected no more than 1 year prior to their enrollment ([@B16]; [@B27]), these data suggest that levels of antibodies to ASP kept increasing following the first year of infection in Pat \#20. Besides, as observed for Pat \#7 ([Figure 2](#F2){ref-type="fig"}), increased levels of anti-ASP antibodies in the plasma of Pat \#20 were detected concomitantly to a phase of viremia decline. Altogether, these results suggest that the magnitude of the humoral response to ASP decreases under ART.

###### 

Immuno-virological parameters of the patients belonging to the cohort ANRS CO2 SEROCO.

  **Patient**   **Ethnical origin**   **Time post-inclusion (years)**   **ART**       **Viremia (copies of HIV-1 RNA/mL of blood)**   **CD4 T cells/μL of blood**
  ------------- --------------------- --------------------------------- ------------- ----------------------------------------------- -----------------------------
  Pat\#20       European              0                                 No            125430                                          1200
                                      2,5                               No            4931                                            690
                                      7                                 AZT-DDC       67722                                           139
                                      13,5                              AZT-DDC-InR   Undetectable                                    58
  Pat\#21       European              3                                 No                                                            413
                                      15                                3TC-ABC-NVP                                                   572
  Pat\#22       European              2,5                               No                                                            805
                                      8,5                               3TC-AZT-IDV                                                   171
  Pat\#23       European              3,5                               No                                                            514
                                      15                                AZT-DDI                                                       558
  Pat\#24       European              2,5                               No                                                            720
                                      10,75                             AZT-DDC-SQV                                                   768
  Pat\#25       European              1,5                               No                                                            791
                                      14,5                              ABC-DDI-EFV                                                   649
  Pat\#26       European              2,5                               No                                                            600
                                      12,5                              D4T-NVP-SqR                                                   1087
  Pat\#27       European              5                                 No                                                            350
                                      13                                3TC-ABC-AZT                                                   776
  Pat\#28       European              4,5                               No                                                            785
                                      12                                3TC-D4T                                                       681
  Pat\#29       European              4,5                               No                                                            500
                                      13                                3TC-D4T                                                       652

AZT, Azidothymidine; DDC, Dideoxycytidine; lnR, Lopinavir; 3TC, Lamivudine; ABC, Abacavir; NVP, Nevirapine; IDV, Indinavir; DDI, Didanosine; SQV, Saquinavir; EFV, Efavirenz; SqR, Saquinavir; D4T, Stavudine.

![Anti-ASP antibody response is not detected after ART initiation in Pat \#20. **(A)** The presence of antibodies against ASP was monitored in the plasma of 10 patients from the SEROCO cohort before and after they initiated ART. Time elapsed between the two time points differ for each patient and goes from 7.5 to 13 years. Each patient is identified by a different symbol. Results obtained with the French seronegative control group (*N* = 20) presented [Figure 1](#F1){ref-type="fig"} are also shown. Signal is expressed as Relative Light Units (RLU). Data shown are the mean of the median of three independent experiments performed in triplicates. **(B)** The anti-ASP antibody response and viremia overtime were monitored in Pat \#20 at four different times post inclusion (at 2.5- and 13.5-years post-inclusion as showed in panel **(A)**, at inclusion and at 7 years post-inclusion). Data shown represent the median (plus min and max values) of one representative experiment performed in triplicates. The star indicates initiation of ART. Values of viremia (number of HIV-1 RNA copies per mL) previously measured in the context of the SEROCO cohort are also represented. Dotted line represents the cut-off value (48,000 RLU).](fmicb-11-00020-g003){#F3}

Antibodies to ASP Are Not Detected in Aviremic HIV Controllers {#S3.SS5}
--------------------------------------------------------------

In plasma samples of Pat \#7 and \#20, increased levels of anti-ASP antibodies were observed during a phase of viremia decline, which could indicate that antibodies targeting ASP contributed to the immune response elicited against HIV-1. To test this hypothesis, we investigated the presence of ASP-specific antibodies in the plasma of HIV-1 controllers (HIC) enrolled in the French ANRS CODEX cohort (Multicentric cohort of HIV-1 patients with extreme progression profiles; [Table 3](#T3){ref-type="table"}) ([@B16]; [@B27]). HIC are patients naturally displaying long-term control of viremia (below 400 HIV RNA copies/mL in the CODEX cohort). As we showed above that the antibody response to ASP fluctuated overtime in patients ([Figures 2](#F2){ref-type="fig"}, [3B](#F3){ref-type="fig"}), we assessed anti-ASP antibodies in the plasma samples collected from these patients at two different times post-enrollment, 2 years apart ([Table 3](#T3){ref-type="table"}). As showed [Figure 4](#F4){ref-type="fig"}, only a background signal was observed in the plasma of these patients, indicating that they did not display antibodies to ASP at any of the two time points that we tested. Of note, we cannot totally exclude the possibility that these patients presented anti-ASP antibodies at earlier stages of the infection, but according to our results, ASP-specific antibodies probably did not contribute to set up the control of viremia in these patients.

###### 

Immuno-virological parameters of the patients belonging to the cohort ANRS HIV Controller CO21 CODEX.

  **Patient**   **Ethnical**        **Time post-**   **Viremia**   **CD4 T**
  ------------- ------------------- ---------------- ------------- -----------
  Pat\#30       European            1                \<20          1238
                                    3                \<20          1917
  Pat\#31       European            0                \<50          809
                                    2                \<40          874
  Pat\#32       European            0                \<10          790
                                    2                \<10          1153
  Pat\#33       African (Maghreb)   4                \<40          1216
                                    6                \<40          1320
  Pat\#34       European            2                41            478
                                    4                \<40          554
  Pat\#35       European            3                \<40          644
                                    5                42            539
  Pat\#36       European            1                \<20          676
                                    3                \<20          628
  Pat\#37       European            3                \<40          452
                                    6                \<40          630
  Pat\#38       European            0                \<20          627
                                    2                \<20          662
  Pat\#39       European            0                \<40          1224
                                    2                \<40          1482
  Pat\#40       African (Maghreb)   0                \<40          421
                                    2                \<40          666
  Pat\#41       European            1                \<20          712
                                    3                23            979
  Pat\#42       European            2                \<20          1382
                                    4                \<20          1509
  Pat\#43       European            2                \<40          966
                                    4                \<40          851
  Pat\#44       European            1                \<40          570
                                    3                \<30          600
  Pat\#45       European            2                \<20          780
                                    4                \<20          1740
  Pat\#46       European            0                \<20          989
                                    2                \<20          761
  Pat\#47       European            0                \<20          584
                                    2                \<20          693
  Pat\#48       European            3                \<20          704
                                    5                \<40          900
  Pat\#49       European            0                \<40          735
                                    2                \<35          836

![Antibodies targeting ASP are not detected in HIV Controllers. LIPS was conducted on the plasma of 20 HIV-1 controllers collected at two different times -2 years apart; year n/year *n*+2- after their inclusion in the CODEX cohort. Results obtained with the French seronegative control group (*N* = 20) presented [Figure 1](#F1){ref-type="fig"} are also shown. Signal is expressed as Relative Light Units (RLU). Data shown are the mean of the median of three independent experiments performed in triplicates. Dotted line represents the cut-off value (48,000 RLU).](fmicb-11-00020-g004){#F4}

Antibodies Target the 26--141 Region of ASP {#S3.SS6}
-------------------------------------------

As a consequence of its overlapping position to *env* in the proviral genome of HIV-1, *asp* encodes for a protein that possesses two highly variable regions (V4 and V5, [Figure 5](#F5){ref-type="fig"}) located at its C-terminal extremity. Conversely, the N-terminal extremity of ASP displays several well-conserved domains: two cysteine triplets and a prolin-rich motif. To delineate the domains of ASP which are targeted by antibodies, we conducted LIPS on the plasma collected from Pat \#7, \#9, \#16, and \#20 with nano-ASP mutants deleted from different domains of ASP ([Figure 5](#F5){ref-type="fig"} and [Supplementary Figure S2](#DS2){ref-type="supplementary-material"}). The deletion of the cysteine triplets (26--189 mutant) and of the C-terminal region (1--141 mutant) encompassing the highly variable motif V4 of ASP did not decrease the signal in any of the plasma tested, indicating that none of these regions are targeted by the antibodies that are present in the plasma of Pat \#7, \#9, \#16, and \#20. On the contrary, the signal was either reduced (Pat \#9 and \#16) or totally suppressed (Pat \#7 and \#20) with the ASP 60--189 mutant lacking the prolin-rich motif. In all the patients, a strong decline was observed when using the prolin-rich motif as antigen (1--62 mutant), although the decline was less important for Pat \#16 than for the three other patients. These results suggest that both the 26--60 region encompassing the PxxP motif and the 60--141 core region of ASP encompassing the highly variable motif V5 are involved in the main epitope of ASP, either directly or indirectly by allowing the proper folding of the epitope.

![Patient antibodies target the 26--141 core region of ASP encompassing the V5 and prolin-rich motifs. **(A)** Scheme of nano-ASP mutants: CCC, cysteine triplets; PxxP, prolin-rich motif; TM, potential transmembrane domain; V4/V5, highly variable motifs 4 and 5. The numbers indicate amino acid positions in ASP. **(B)** LIPS was conducted with nano-ASP mutants on the plasma collected from Pat \#7, \#9, \#16 (collected 37 weeks after ARV cessation), and \#20 (collected 2.5 years after enrollment). For each mutant, the signal was normalized by substracting the signal obtained with the nanoluciferase alone for the same plasma sample. The resulting normalized luminescence is expressed as the percentage of the signal obtained with the full-length form of nano-ASP. Data shown represent the median of the triplicates obtained from one representative experiment.](fmicb-11-00020-g005){#F5}

Discussion {#S4}
==========

In our study, we developed a specific and quantitative luminescent assay to assess the presence of antibodies directed against ASP in the plasma of HIV-1-infected patients. Using this approach, we found anti-ASP antibodies in patients who discontinued ARV (3 of 19) and in ART-naive patients (1 of 10). By contrast, antibodies to ASP were detected neither in aviremic patients under ART nor in ART-naive aviremic HIV--1 controllers. The analysis of ASP-targeted domains showed that both the conserved prolin-rich motif and the core region (60--141) encompassing the highly variable motif V5 are involved in ASP recognition by antibodies. So far, the only variation of ASP that has been specifically associated with a viral subtype (HIV-1 subtype A) is a N-terminal deletion (residues 1--26) ([@B8]). Besides, the C-terminal domain contains most of the inter- and intra-individual variations ([@B8]). Neither the N-terminal nor the C-terminal extremities of ASP seemed to be targeted by antibodies, which thus appear to be dispensable to elicit anti-ASP antibody response. However, we cannot exclude that, in our investigation, the targeting of the variable C-terminal region of ASP might have been underestimated by the use of an ASP antigen (derived from BRU/LAV) whose sequence might differ from the ones found in patients.

In our study, anti-ASP antibodies were detected in 10--15% of the HIV-1-infected individuals, which seems less than previously suggested by the study of C. Vaquero, a least for patients in advanced stages of infection ([@B30]). However, humoral responses to other auxiliary and regulatory proteins of HIV-1 in infected subjects ranged from 12% (Tat; [@B25]) to 25--26% (Vif and Vpr; [@B24]; [@B23]), and up to 43% (Vpu; [@B24]). The frequency of anti-ASP antibody response is also consistent with previous studies showing humoral responses against HBZ in 10% of the HTLV-1 infected subjects ([@B11]; [@B28]). The CD8+ T cell response targeting ASP was described in approximately 30% of the patients ([@B3]; [@B4]). This higher frequency might be inferred to the targeting by CD8+ T cells of highly conserved linear epitopes from intracellular antigens, contrary to antibodies which target extracellular antigens. Humoral responses to HIV-1 Gag, Pol and Env proteins were described to be dependent of HIV-1 replication and to strongly decline during ART ([@B31]; [@B14]; [@B33]; [@B10]). In line with these results, we did not detect any antibodies to ASP in aviremic patients under ART. In addition, antibodies to ASP were no longer detected in Pat \#20 at two different times after ART initiation, further suggesting that the prolonged aviremia under ART lead to a decrease of antibody responses to ASP. However, for Pat \#9 and \#16 who presented antibodies to ASP at the earliest time point tested after ARV cessation, we can speculate a persistence of this response regarding the short duration of their ARV (7 and 4 weeks, respectively). As suggested by the lack of detection of antibodies targeting ASP in the plasma of HIV-1 controllers in our study, a detectable level of viral replication might be needed to induce a humoral response to ASP. Interestingly, ASP was recently described at the membrane of viral particles released by chronically infected cells following their *in vitro* reactivation ([@B1]). If ASP is indeed present at the surface of viral particles *in vivo*, it might partially explain why we did not detect antibodies against ASP in patients displaying very low or undetectable viral loads. However, this hypothesis is challenged by the fact that we observed a peak of antibodies to ASP concomitantly to a phase of viremia decline in Pat \#7, and during a phase of low viremia in Pat \#20. As our results suggest that anti-ASP response is dynamic overtime, a deeper study of the relationship between viremia and the antibody response against ASP would require the analysis of these parameters in plasma sampled from patients at shorter temporal intervals.

This could also indicate that the *in vivo* production of ASP occurs when viral production decreases, contrary to what was suggested by the study of [@B1], but in line with a previous study which suggested that ASP is rather expressed during the chronical phase than during the acute phase of the disease ([@B4]). Besides, we recorded an increase in ASP-specific antibody titers during the 2.5 years following enrollment in Pat \#20, further suggesting that antibody response to ASP is developed after acute infection. Though a recent study reported the concomitant expression of sense and antisense transcripts in infected cells ([@B19]), several studies conducted by our group and by others showed that antisense transcription preferentially occurs in non-producing infected cells ([@B17]; [@B15]; [@B18]; [@B26]; [@B32]). This consideration is of outstanding interest as several studies previously proposed antisense transcription as a common feature of viral latency ([@B17]; [@B15]; [@B18]; [@B26]; [@B32]). Altogether, we developed a specific and quantitative assay that allows us to evaluate anti-ASP antibodies in the plasma of HIV-1-infected patients. Our results provide the first confirmation of the study conducted in 1995 by C. Vaquero's group ([@B30]) and describe individual variations in ASP-specific antibody titers during the infection course. Though observed on a small number of subjects, the results of our pilot evaluation point the importance to study ASP and its antibody response during the different stages of HIV-1 infection. In the future, it would be of great interest to increase the number of serum samples (from HIV-1 negative and positive individuals) tested and to study the long-term ASP-specific antibody response in untreated, chronically infected subjects and to assess its potential impact on disease outcomes.
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